Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global 麻豆原创s Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) - Drugs In Development, 2022, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.
Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.
Report Highlights
Global 麻豆原创s Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 21, 130, 152, 12, 15, 233, 55 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 21, 23, 9, 40 and 9 molecules, respectively.
Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global 麻豆原创s Direct鈥檚 proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it鈥檚 most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global 麻豆原创s Direct Report Coverage
Multiple Myeloma (Kahler Disease) - Overview
Multiple Myeloma (Kahler Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
Multiple Myeloma (Kahler Disease) - Drug Profiles
Multiple Myeloma (Kahler Disease) - Dormant Projects
Multiple Myeloma (Kahler Disease) - Discontinued Products
Multiple Myeloma (Kahler Disease) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
List of Tables
Number of Products under Development for Multiple Myeloma (Kahler Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Multiple Myeloma (Kahler Disease) - Dormant Projects, 2022
Multiple Myeloma (Kahler Disease) - Discontinued Products, 2022
List of Figures
List of Figures
Number of Products under Development for Multiple Myeloma (Kahler Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
2Seventy Bio Inc
4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
Abbisko Therapeutics Co Ltd
AbbVie Inc
Abcuro Inc
ABL Bio Inc
Actinium Pharmaceuticals Inc
Active Biotech AB
Adicet Bio Inc
Affimed GmbH
AKSO Biopharmaceutical Inc
Alabama Drug Discovery Alliance
Allogene Therapeutics Inc
Alloplex Biotherapeutics Inc
Alphamab Oncology
Ambrx Biopharma Inc
Amgen Inc
Anaveon AG
Antaimmu BioMed Co Ltd
Antengene Corp Ltd
Antion Biosciences SA
APIM Therapeutics AS
APO-T BV
Apollo Therapeutics LLC
Arcellx Inc
Arch Oncology Inc
Arcus Biosciences Inc
Ariz Precision Medicine Inc
Arjuna Therapeutics
Arovella Therapeutics Ltd
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Asylia Therapeutics Inc
Auransa Inc
Aurigene Discovery Technologies Ltd
Autolus Therapeutics Plc
Ayala Pharmaceuticals Inc
Bantam Pharmaceutical LLC
Bayer AG
BeiGene Ltd
Beijing Immunochina Pharmaceuticals Co Ltd
Beijing Jingda Biotechnology Co Ltd
Beijing Mabworks Biotech Co Ltd
Beijing Menlo Biotechnology Co Ltd
Beijing Sunbio Biotech Co Ltd
Bellicum Pharmaceuticals Inc
Betta Pharmaceuticals Co Ltd
BeyondSpring Inc
Biocad
BioCurate Pty Ltd
Biohaven Pharmaceutical Holding Company Ltd
Biolexis Therapeutics Inc
BioLineRx Ltd
Biomea Fusion Inc
BioTheryX Inc
BioVie Inc
Bivictrix Therapeutics PLC
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
Bristol-Myers Squibb Co
C4 Therapeutics Inc
Calithera Biosciences Inc
Cantex Pharmaceuticals Inc
Carbiogene Therapeutics Co Ltd
Caribou Biosciences Inc
CARsgen Therapeutics Ltd
Cartesian Therapeutics Inc
CASI Pharmaceuticals Inc
CDR-Life Inc
Cell Source Inc
CellCentric Ltd
Cellectar Biosciences Inc
Cellectis SA
Cellenkos Inc
Cellestia Biotech AG
Cello Therapeutics Inc
Cellular Biomedicine Group Inc
Celularity Inc
Celyad Oncology SA
Centrax International Inc
Ceptur Therapeutics Inc
Checkpoint Therapeutics Inc
Cheetah Cell Therapeutics Co Ltd
Chengdu Zenitar Biomedical Technology Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimerix Inc
China Immunotech (Beijing) Biotechnology Co Ltd
Chinook Therapeutics Inc
Chong Kun Dang Pharmaceutical Corporation
Chongqing Precision Biotech Co Ltd
CiMaas BV
Cleave Therapeutics Inc
Compugen Ltd
Convalife
Corvus Pharmaceuticals Inc
CRISPR Therapeutics AG
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Curocell Inc
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
CytoImmune Therapeutics Inc
Cytovia Holdings Inc
Daiichi Sankyo Co Ltd
Dayton Therapeutics AG
DexTech Medical AB
Diverse Biotech Inc
Dragonfly Therapeutics Inc
Dynamic Cell Therapies Inc
Eli Lilly and Co
Elpis Biopharmaceuticals Corp
EpimAb Biotherapeutics Inc
Epizyme Inc
Eternity Bioscience Inc
eTheRNA Immunotherapies NV
Eugia Pharma Specialties Ltd
Eureka Therapeutics Inc
ExCellThera Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fera Pharmaceuticals LLC
Fortis Therapeutics Inc
Fusion Pharmaceuticals Inc
Gadeta BV
Galapagos NV
Galileo Research srl
Gamida Cell Ltd
Genentech USA Inc
Genmab AS
Genrix (Shanghai) Biopharmaceutical Co Ltd
Geron Corp
Gilead Sciences Inc
Ginkgo BioWorks Inc
Gliknik Inc
GlycoMimetics Inc
Glycostem Therapeutics BV
GlyTR Therapeutics Inc
GP Pharm SA
GPCR Therapeutics Inc
Gracell Biotechnologies Inc
GSK plc
GT Biopharma Inc
Guangzhou Bio-gene Technology Co Ltd
HaemaLogix Pty Ltd
Hangzhou DAC Biotech Co Ltd
Hangzhou Sumgen Biotech Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
Harpoon Therapeutics Inc
Hebei Senlang Biotechnology Co Ltd
Heidelberg Pharma AG
Helix BioPharma Corp
Helocyte Biosciences Inc
Henan Genuine Biotech Co Ltd
Hinova Pharmaceuticals Co Ltd
HitGen Inc
HK inno.N Corp
Holy Stone Healthcare Co Ltd
HRAIN Biotechnology Co Ltd
Hummingbird Bioscience Pte Ltd
Hunan Siweikang Therapeutics Ltd
HuniLife Biotechnology Inc
Hutchison MediPharma Ltd
I-Mab
iCell Gene Therapeutics LLC
Iceni Pharmaceuticals Ltd
Ichnos Sciences Inc
IDAC Theranostics Inc
IDP Discovery Pharma SL
IGM Biosciences Inc
Immix BioPharma Inc
ImmuneCyte Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmuneTarget Inc
ImmunityBio Inc
Immunotech Biopharm Ltd
Immunwork Inc
Incyte Corp
Indapta Therapeutics Inc
Inflection Biosciences Ltd
Inmune Bio Inc
InnoCare Pharma Ltd
Innovent Biologics Inc
Intra-Immusg Pvt Ltd
Inventiva SA
IO Biotech Inc
Io Therapeutics Inc
Ionis Pharmaceuticals Inc
Ionova Life Science Co Ltd
Istesso Ltd
iTeos Therapeutics Inc
Iterion Therapeutics Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Chai Tai Fenghai Pharmaceutical Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Jiangsu Zhengda Fenghai Pharmaceutical Co Ltd
Jiangxi Shanxing Biotechnology Co Ltd
JN Biosciences LLC
Johnson & Johnson
JSK Therapeutics Inc
Jubilant Therapeutics Inc
Juventas Cell Therapy Ltd
JW Pharmaceutical Corp
K36 Therapeutics Inc
KAHR medical Ltd
Kangpu Biopharmaceuticals Ltd
Kartos Therapeutics Inc
Karyopharm Therapeutics Inc
Kesios Therapeutics Ltd
KeyMed Biosciences Inc
Kirilys Therapeutics Inc
Kite Pharma Inc
Klyss Biotech Inc
Kodikaz Therapeutic Solutions Inc
Komipharm International Co Ltd
Kronos Bio Inc
KYAN Therapeutics Inc
Kymab Ltd
Laekna Therapeutics Shanghai Co Ltd
Lantern Pharma Inc
LAVA Therapeutics NV
Leadiant Biosciences Inc
Legend Biotech Corp
Les Laboratoires Servier SAS
Leukogene Therapeutics Inc
Ligand Pharmaceuticals Inc
LintonPharm Co Ltd
Lokon Pharma AB
Lotus Pharmaceutical Co Ltd
Loxo Oncology Inc
Luminary Therapeutics Inc
Luminus Biosciences Inc
Luye Pharma Group Ltd
Mablink Bioscience
Machavert Pharmaceuticals LLC
Marker Therapeutics Inc
Max Biopharma Inc
MediGene AG
MedPacto Inc
Mendus AB
Merck & Co Inc
Millennium Pharmaceuticals Inc
Miltenyi Biomedicine GmbH
MimiVax LLC
MiNK Therapeutics Inc
Modulation Therapeutics Inc
Molecular Partners AG
Molecular Templates Inc
Monte Rosa Therapeutics Inc
Morphogenesis Inc
MorphoSys AG
Multitude therapeutics Inc
Mustang Bio Inc
Mycovia Pharmaceuticals Inc
Nanexa AB
Nanjing Aimeifei Biomedical Technology Co Ltd
Nanjing Bioheng Biotech Co Ltd
Nanjing IASO Biotherapeutics Co Ltd
Nektar Therapeutics
Neomics Pharmaceuticals LLC
Neonc Technologies Inc
Nerviano Medical Sciences SRL
Newave Pharmaceutical Inc
NewBay Medical Technology Co Ltd
NGM Biopharmaceuticals Inc
Northlake International LLC
Novartis AG
Oncodesign SA
OncoFusion Therapeutics Inc
Oncolytics Biotech Inc
Oncolyze Inc
OncoMyx Therapeutics Inc
Onconova Therapeutics Inc
OncoPep Inc
Oncopeptides AB
OncoTartis Inc
OncoTherapy Science Inc
One World Cannabis Ltd
ONK Therapeutics Ltd
Ono Pharmaceutical Co Ltd
Onward Therapeutics SA
Opna Bio SA
Orgenesis Inc
ORIC Pharmaceuticals Inc
Origincell Technology Group Co Ltd
Otsuka Pharmaceutical Co Ltd
Oxcia AB
Paras Biopharmaceuticals Finland Oy
PentixaPharm GmbH
PersonGen Anke Cellular Therapeutics Co Ltd
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pfizer Inc
Pharma Mar SA
Phi Pharma SA
PI Therapeutics Ltd
Pimera Inc
Pinotbio Inc
Poseida Therapeutics Inc
Precision Biosciences Inc
Pregene ShenZhen Biotechnology Co Ltd
Prelude Therapeutics Inc
Prescient Therapeutics Ltd
Promontory Therapeutics Inc
Protheragen Inc
Qilu Pharmaceutical Co Ltd
Quadriga BioSciences Inc
Qwixel Therapeutics LLC
Rapa Therapeutics LLC
RAPT Therapeutics Inc
RE-Stem Biotech Co Ltd
Recordati SpA
Regeneron Pharmaceuticals Inc
Remd Biotherapeutics Inc
SA Science Inc
Salarius Pharmaceuticals Inc
Sana Biotechnology Inc
Sanofi
Seagen Inc
SELLAS Life Sciences Group Inc
Senhwa Biosciences Inc
Shandong New Time Pharmaceutical Co Ltd
Shanghai Biomed-Union Biotechnology Co Ltd
Shanghai Bioray Laboratory Inc
Shanghai GeneChem Co Ltd
Shanghai Henlius Biotech Inc
Shanghai HyaMab Biotech Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Keqi Pharmaceutical Technology Co Ltd
Shanghai Novamab Biopharmaceuticals Co Ltd
Shanghai Theorion Pharmaceutical Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shenogen Pharma听Group Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Neptunus Institute of Pharmaceutical Technology Co Ltd
Shenzhen Targetrx Inc
Shuttle Pharmaceuticals Inc
Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SignalRx Pharmaceuticals Inc
SignPath Pharma Inc
Sorrento Therapeutics Inc
Spectrum Pharmaceuticals Inc
Sphaera Pharma Pte Ltd
SpringWorks Therapeutics Inc
Starton Therapeutics Inc
SteroTherapeutics LLC
Sumitomo Dainippon Pharma Oncology, Inc
Sunnycell Therapeutics Ltd
Sunomix Therapeutics
Sutro Biopharma Inc
Suzhou JiSheng Pharmaceutical Co Ltd
Suzhou Maximum Bio-tech Co Ltd
Synactix Pharmaceuticals Inc
SynDevRx Inc
T-Cure Bioscience Inc
T-CURX GmbH
TaiRx Inc
Takeda Pharmaceutical Co Ltd
Targazyme Inc
Targovax ASA
TC BioPharm Ltd
Telix Pharmaceuticals Ltd
Theolytics Ltd
TheraBioPharma Inc
Tianweiyuan and Biomedicine Shanghai Co Ltd
TiCARos Co Ltd
Tiziana Life Sciences Plc
Tmunity Therapeutics Inc
Transgene Biotek Ltd
Triterpenoid Therapeutics Inc
Triumvira Immunologics Inc
TSD Life Sciences
TTY Biopharm Co Ltd
Up Therapeutics Inc
UTC Therapeutics Inc
VaxCell Biotherapeutics Co Ltd
Vaxil Bio Therapeutics Ltd
Verastem Inc
Vichem Chemie Research Ltd
Vincerx Pharma Inc
Virtuoso Therapeutics Inc
Visterra Inc
Vycellix Inc
Vyriad Inc
Wellington Zhaotai Therapies Ltd
Wigen Biomedicine Technology (Shanghai) Co Ltd
WindMIL Therapeutics Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Wuhan YZY Biopharma Co Ltd
XBiotech Inc
Xbrane Biopharma AB
XEME BioPharma Inc
Xencor Inc
Xi'An Yufan Biotechnology Co Ltd
Xiangxue Life Sciences
XNK Therapeutics AB
Zhengda Tianqing Pharmaceutical Group Co Ltd
Zovis Pharmaceuticals
听
听
*If Applicable.